Searchable abstracts of presentations at key conferences in endocrinology

ea0016me9 | (1) | ECE2008

Prolactin: an underestimated hormone

Gullu Sevim

Prolactin (PRL) is a peptide hormone and secreted by the lactotrophs in the anterior pituitary gland. Its secretion is regulated by the hypothalamus and under control of inhibitory effect of mainly dopamin. Gamma-aminobutyric acid (GABA) and other unidentified prolactin-release-inhibiting factors has also effects on PRL secretion. Thyrotropin-releasing hormone (TRH) is a prolactin-releasing factor. Vasoactive intestinal peptide (VIP), oxytocin and galanin are the other probabl...

ea0037ep882 | Thyroid cancer | ECE2015

The rare intracellular RET mutation p.S891A in a Turkish family with hereditary medullary thyroid carcinoma

Keskin Caglar , Gullu Sevim

Introduction: Medullary thyroid carcinoma (MTC) could be familial in 30% of cases. Here, we report a family of FMTC with rarely seen RET p.S891A mutation.Case presentation: A 49-year-old man presented with a single nodule in the left lobe of thyroid. Thyroid ultrasonography (US) showed a nodule and pathological cervical lymph nodes. There was no relevant family history. Fine-needle aspiration cytology (FNAC) of the nodule was consistent with a diagnosis ...

ea0041ep1141 | Thyroid cancer | ECE2016

Relation of F-18 FDG PET/CT positivity with tumor cytopathology and molecular markers in malignant and benign thyroid tumors

Cakmak Guzin , Imge Aydogan Berna , Gullu Sevim

Introduction: The role of F-18 FDG PET/CT in follow-up of differentiated thyroid cancer (DTC) is well established. Molecular markers were shown to be related with malignancy risk of thyroid nodules and prognosis of DTC. The goal of this study was to assess the relation of molecular markers such as NIS, Galectin-3, PTEN, Ki-67, p53 with PET positivity and malignancy of thyroid.Methods/design: We evaluated patients who had 18-FDG uptake in thyroid gland at...

ea0020p90 | Thyroid | ECE2009

Long-term follow-up of antithyroid peroxidase antibodies in patients with Hashimoto’s thyroiditis

Agbaht Kemal , Dagdelen Iffet , Gullu Sevim

Background: Although a number of studies show that the serum levels of antithyroid peroxidase antibodies (TPO-Ab) in patients with Hashimoto’s thyroiditis decline during levothyroxine treatment, only a few provide quantitative data. The objective of the present study was to provide this information.Methods: This was a retrospective study of TPO-Ab concentrations in 44 women and 4 men (median age 45.5 years; range 17–76 years) with Hashimoto&#14...

ea0020p654 | Reproduction | ECE2009

Serum androgen levels correlate well with metabolic parameters in polycystic ovary syndrome

Agbaht Kemal , Yerlikaya Halis , Gullu Sevim

Background: In polycystic ovary syndrome (PCOS), in response to stimulation by luteinizing hormone (LH), the ovarian theca cell synthesizes androgens. However, associations of serum androgen levels with metabolic parameters yet to be determined. We aimed to investigate these associations.Methods: We retrospectively evaluated our outpatient admission records for PCOS, hirsutism, oligomenorrhea, or secondary amenorrhea. PCOS diagnosis was made after exclud...

ea0056p813 | Pituitary - Clinical | ECE2018

The association between Ki-67 proliferation index, P53 expression, mitotic index, tumor invasion and the risk of recurrence in pituitary adenomas

Hasanov Rovshan , Aydogan Berna Imge , Gullu Sevim

Background: The 4th edition of World Health Organization (WHO) classification of pituitary tumors recommended evaluation of tumor proliferation and invasion to identify aggressiveness. We aimed to assess the relationship between Ki-67, mitotic index, P53 expression, invasion and recurrence risk in pituitary adenomas.Methods: Among 601 patients who underwent TN/TS adenomectomy between 2001 and 2016, 101 patients (16.8%) who had tumors with Ki-67 index &#8...

ea0056p834 | Pituitary - Clinical | ECE2018

Two cases of silent corticotroph adenomas

Cinel Murat , Canlar Sule , Gullu Sevim

Introduction: Pituitary adenomas are mostly benign tumors which may be clinically functioning or non-functioning and ACTH secreting tumors make up 15% of them. Up to 20% of corticotroph adenomas which don’t have any biochemical or clinical evidence of hypercortisolism are known as silent corticotroph adenomas.Case 1: A 54 years old male presented with blurred of vision and headache that increasing in severity within six years. Physical examination a...

ea0022p122 | Bone/Calcium | ECE2010

Primary hyperparathyroidism: laboratory associations and thyroid pathologies

Agbaht Kemal , Eraslan Emrah , Karaarslan Ozlem , Gullu Sevim

Background: Diagnosis of primary hyperparathyroidism (PHP) is sometimes challenging and needs supportive evidence. We aimed to document laboratory findings (ratio of calcium clearance to creatinine clearance, ratio of phosphorus clearance to creatinine clearance, serum chloride to phosphorus ratio, serum alkaline phosphatase) and thyroid pathologies associated with established PHP that may provide supplementary clues to the diagnosis.Methods: We document...

ea0020p653 | Reproduction | ECE2009

Hyperprolactinemia in polycystIc ovary syndrome

Agbaht Kemal , Yerlikaya Halis , Demir Ozgur , Gullu Sevim

Background: Hyperprolactinemia is frequently reported with polycystic ovary syndrome (PCOS). However, there is a controversy whether they share a common mechanism or have cause–result relationship or just are coincidental. The objective of the present study was to identify the cause of hyperprolactinemia in patients with PCOS.Methods: We retrospectively evaluated our outpatient admission records for PCOS, hirsutism, oligomenorrhea, or secondary amen...

ea0090p781 | Thyroid | ECE2023

Quality of Life in Patients with Papillary Thyroid Cancer Assessed with The Turkish Version of The Thyroid Related Patient-Reported Outcome Questionnaire ThyPRO: A Prospective Single Center Study

Cıkın Boztuğ Cansu , Begum Bahcecioglu Mutlu Adile , Gullu Sevim

Background: Although the survival rate of papillary thyroid cancer is over 95%, the diagnosis of ’cancer’ and fear of recurrence may impair the quality of life of patients. There is no specific scale for patients with thyroid cancer, scales that can be used in the course of all chronic diseases and include the concept of general health are used to evaluate the quality of life in these patients. We aimed to evaluate the validity of the Thyroid Specific Quality of Life...